Join our daily newsletter At The Bell to receive exclusive market insights
- PolyNovo (PNV) has received its first order of NovoSorb BTM in Germany, Austria and Switzerland
- This product is a synthetic dressing used to treat severe burns
- The first batch of the NovoSorb BTM were shipped to hospitals in preparation for the first surgery
- The company launched the dressing just last week at a burns conference in Austria
- PolyNovo is up 11 per cent on the market and trading for $2.83 per share
PolyNovo (PNV) has received its first order of NovoSorb BTM in Germany, Austria and Switzerland.
The first batch of NovoSorb BTM were shipped to hospitals in preparation for the first surgery.
NovoSorb BTM is a synthetic dressing that is used to treat severe burns and wounds where the patient has suffered a significant loss of flesh.
The company launched the product just last week at a burns conference in Austria. Numerous surgeons expressed their interest in NovoSorb and stated their intentions on using the product in the near future.
PolyNovo and PolyMedics Innovations hosted 70 surgeons for dinner at the Austrian conference, where CEO Paul Brennan spoke about the technology and its partnership with PolyMedics.
At the conference, Dr Marcus Wagstaff presented a clinical overview of the Royal Adelaide Hospital’s experience using NovoSorb.
“PolyMedics facilitated an impressive launch and demonstrated their excellent and established relationships with surgeons and hospitals in Germany, Austria and Switzerland,” Paul said.
“The enthusiasm and engagement of surgeons for NovoSorb BTM is very exciting and likely to bring further product sales in the near term,” he added.
“When we announced our EU approval in mid-December we said we expected near term sales. We have achieved that now and better still we have the first patients being treated,” Chairman David Williams told the market.
PolyNovo is up 11 per cent on the market and trading for $2.83 per share at market close.
